Pharmaceutical Executive-11-01-2011

Red Light on the Access Autobahn

Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?

We ask three managers building Greenfield plants to rationalize and defend their decisions

How is the world's dedicated pharma leader going to improve its positioning in Russia? Pfizer's country manager Christian Holmer comments.

Five years of legislation in the Russian pharmaceutical industry

With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.

Foreign player? Choose a local partner

The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?

Clamor for critical therapies prompts probes of prices, production practices.

Know your strengths, then expand

The bigger the company, the thicker the sclerosis, the more they need to suck out the fat

Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.

Russia had been a country in flux-monetary crises, corruption scandals, oil surpluses, etc. But no multinational should be scared off by the market anymore, not with its economy on the verge of breaking out.

The triple bottom line

A celebration of achievement

If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.

Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.

Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?